Key result
Septal myectomy during AVR shows similar hospital mortality and pacemaker rates versus AVR alone.
Why the study?
Concerns have been raised regarding higher complication rates, such as permanent pacemaker implantation, associated with concomitant septal myectomy during open AVR for asymmetric secondary basal septal hypertrophy.
Does concomitant septal myectomy during elective aortic valve replacement increase the risk of hospital mortality or permanent pacemaker implantation?
Cohort (n=2,199)
No
Does concomitant septal myectomy during elective aortic valve replacement increase the risk of hospital mortality or permanent pacemaker implantation?
Absolute Event Rate: 2.1% vs 1.6%
p-value: p=1.000
Concomitant septal myectomy during elective aortic valve replacement is safe and does not increase hospital mortality or the need for permanent pacemaker implantation.
Concomitant myectomy was associated with similar risks in this cohort; hypothesis-generating and should not yet change practice.
BACKGROUND: Septal myectomy during open aortic valve replacement (AVR) is an effective surgical treatment for asymmetric secondary basal septal hypertrophy. Concerns regarding higher rates of complications associated with this procedure have been raised - such as permanent pacemaker implantation. The aim of this study was to compare outcomes and complications of patients with and without concomitant septal myectomy using propensity score matching applied to a large, consecutive single center cohort. METHODS: A total of 2199 consecutive patients undergoing either AVR with concomitant myectomy (AVR-M, N.=212) or AVR alone (N.=1987) were analyzed (2009-2015). Patients with previous cardiac or emergency surgery, concomitant cardiac procedures and endocarditis were excluded. As reference to previously published data, patient characteristics and outcomes of the overall cohort were examined and for comparison between groups propensity score matching utilized. RESULTS: In the unmatched cohort, AVR-M patients were older (71.2±8 vs. 67.6±10 years, P<0.001) and more often female (68% vs. 37%, P<0.001) in comparison to patients receiving only AVR. After matching (N.=374) no significant difference in baseline features was evident. No significant difference in hospital mortality (2.1% vs. 1.6%, P=1.000) and pacemaker-implantation rate (5.3% vs. 3.7%, P=0.621) was observed. Mid-term survival was comparable between the two groups (86.1±5% vs. 84.4±5% after 6 years, P=0.957). The overall patient cohort showed a survival comparable to that of an adjusted regional normal population (P=0.178). CONCLUSIONS: This study demonstrates that concomitant myectomy in patients undergoing AVR is a safe surgical technique resulting in comparable hospital mortality and mid-term survival. Concomitant septal myectomy seems not to be associated with an increased pacemaker implantation rate.
No takes yet. Share an insight, caveat, or question.
Aspern et al. (2021) conducted a cohort in Aortic valve replacement with or without asymmetric secondary basal septal hypertrophy (n=2,199). Aortic valve replacement with concomitant septal myectomy vs. Aortic valve replacement alone was evaluated on Hospital mortality (p=1.000). Concomitant septal myectomy during aortic valve replacement yielded similar hospital mortality (2.1% vs 1.6%, P=1.000) and pacemaker implantation rates (5.3% vs 3.7%, P=0.621) compared to AVR alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: